USEFULNESS OF THERAPEUTIC MONITORING OF INFLIXIMAB IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE.
Utilidad de la monitorización terapéutica de infliximab en el manejo de la enfermedad inflamatoria intestinal
Author
Quera, Rodrigo; Clínica Las Condes
Moreno, Mauricio; Clínica Las Condes
Simian, Daniela; Clínica Las Condes
Ibáñez, Patricio; Clínica Las Condes
Lubascher, Jaime; Clínica Las Condes
Figueroa, Carolina; Clínica Las Condes
Flores, Lilian; Clínica Las Condes
Kronberg, Udo; Clínica Las Condes
Fluxá, Daniela; Clínica Las Condes
Abstract
Background: Primary non-response and secondary loss of response (LOR) are significant problems of biological therapy for inflammatory bowel disease (IBD). Therapeutic drug monitoring (TDM) in IBD patients receiving these drugs can improve outcomes. Aim: To measure serum infliximab levels and anti-infliximab antibodies (ATI) in patients with IBD post-induction phase and during maintenance therapy assessing the clinical course of IBD. Patients and methods: Prospective study of IBD patients receiving infliximab between July 2016-May 2017. Group-A included patients who received induction therapy while Group-B included patients who were in maintenance therapy. TDM was performed in serum samples collected at weeks-14 and 30 in Group-A and before the infliximab maintenance dose in Group-B. Clinical scores, fecal calprotectin and endoscopic score were also evaluated. Results: Of 14 patients in Group-A, 57% achieved endoscopic response. Median serum infliximab concentrations at week-14 and 30 were 2.65 AU/mL (0.23-32.58) and 2.3 AU/mL (0.3-16.8), respectively. Patients with mucosal healing had non-significantly higher median infliximab concentrations at week-14, as compared to week 30 (median 3.2 vs 2.2 AU/ml, respectively, p 0.6). ATI >10 ug/mL were found in one and seven patients at week-14 and 30, respectively. At 52 weeks of follow-up, four patients (31%) had LOR. Group-B included 36 patients, 33% had LOR. Median serum concentrations of infliximab were 1.4 AU/mL (0.27-7.03). No significant differences in serum infliximab concentration were observed between patients in remission and those with inflammatory activity. Seventeen patients had ATI >10 ug/mL. Conclusions: Clinical algorithms using TDM might help to optimize the pharmacological therapy of IBD. Background: Primary non-response and secondary loss of response (LOR) are significant problems of biological therapy for inflammatory bowel disease (IBD). Therapeutic drug monitoring (TDM) in IBD patients receiving these drugs can improve outcomes. Aim: To measure serum infliximab levels and anti-infliximab antibodies (ATI) in patients with IBD post-induction phase and during maintenance therapy assessing the clinical course of IBD. Patients and methods: Prospective study of IBD patients receiving infliximab between July 2016-May 2017. Group-A included patients who received induction therapy while Group-B included patients who were in maintenance therapy. TDM was performed in serum samples collected at weeks-14 and 30 in Group-A and before the infliximab maintenance dose in Group-B. Clinical scores, fecal calprotectin and endoscopic score were also evaluated. Results: Of 14 patients in Group-A, 57% achieved endoscopic response. Median serum infliximab concentrations at week-14 and 30 were 2.65 AU/mL (0.23-32.58) and 2.3 AU/mL (0.3-16.8), respectively. Patients with mucosal healing had non-significantly higher median infliximab concentrations at week-14, as compared to week 30 (median 3.2 vs 2.2 AU/ml, respectively, p 0.6). ATI >10 ug/mL were found in one and seven patients at week-14 and 30, respectively. At 52 weeks of follow-up, four patients (31%) had LOR. Group-B included 36 patients, 33% had LOR. Median serum concentrations of infliximab were 1.4 AU/mL (0.27-7.03). No significant differences in serum infliximab concentration were observed between patients in remission and those with inflammatory activity. Seventeen patients had ATI >10 ug/mL. Conclusions: Clinical algorithms using TDM might help to optimize the pharmacological therapy of IBD.
Metadata
Show full item recordRelated items
Showing items related by title, author, creator and subject.
-
Adults patients with influenza, clinical evolution, cost and diagnosis related groups, four years results. Clinica Dávila, Santiago, Chile
Maquilón O., César; Munster C., Elizabeth; Tapia P., Cecilia; Antolini T., Mónica; Cabrera V., Sebastián; Arpón F., Paula. Revista Chilena de Enfermedades Respiratorias; Vol 34 No 2 (2018): Revista chilena de enfermedades respiratorias; 102-110 -
Portugués: EL MÉTODO DINÁMICO DE TERAPIA OCUPACIONAL EN LOS CUIDADOS PALIATIVOS Y LA FINALIZACIÓN DE LA VIDA EN LA CLÍNICA INFANTIL
de Almeida Lino, Eduardo Augusto; Paris Saciloti, Isabelle. Revista de Estudiantes de Terapia Ocupacional; Vol. 9 Núm. 2 (2022): Revista de Estudiantes de Terapia Ocupacional; 18-23 -
Resultados del programa de implantes cocleares de Clínica Las Condes a 20 años de su inicio: Serie clínica 1994-2015
Ribalta L,Gloria; Goycoolea V,Marcos; Cardemil M,Felipe; Cohen V,Mauricio; Ried G,Ernesto; Labatut P,Tomas; Levy G,Raquel; Alarcón F,Pilar; Sierra G,Mónica; Díaz S,Constanza. Revista de otorrinolaringología y cirugía de cabeza y cuello v.78 n.3 2018